Donate Help Contact The AHA Sign In Home
American Heart Association
Circulation
Search: search_blue_button Advanced Search
Circulation. 2001;104:676-681
doi: 10.1161/hc3101.093765
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Stetson, S. J.
Right arrow Articles by Torre-Amione, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Stetson, S. J.
Right arrow Articles by Torre-Amione, G.
Related Collections
Right arrow Growth factors/cytokines
Right arrow Hypertrophy
Right arrow CV surgery: transplantation, ventricular assistance, cardiomyopathy

(Circulation. 2001;104:676.)
© 2001 American Heart Association, Inc.


Clinical Investigation and Reports

Cardiac Hypertrophy After Transplantation Is Associated With Persistent Expression of Tumor Necrosis Factor-{alpha}

Sonny J. Stetson, BS; Ale Perez-Verdia, MD; Wojceich Mazur, MD; John A. Farmer, MD; Michael M. Koerner, MD, PhD; Donald G. Weilbaecher, MD; Mark L. Entman, MD; Miguel A. Quiñones, MD; George P. Noon, MD; Guillermo Torre-Amione, MD, PhD

From Departments of Medicine (S.J.S., A.P.-V., W.M., J.A.F., M.M.K., M.L.E., M.A.Q., G.T.-A.), Thoracic and Cardiovascular Surgery (G.P.N.), and Cardiac Pathology (D.G.W.), and Sections of Cardiology and Cardiovascular Sciences (S.J.S., A.P.-V., W.M., J.A.F., M.M.K., M.L.E., M.A.Q., G.T.-A.), The DeBakey Heart Center and The Gene and Judy Campbell Lab for Cardiac Transplant Research, The Winters Center for Heart Failure Research, Baylor College of Medicine and The Methodist Hospital, Houston, Tex.

Reprint requests to Guillermo Torre-Amione, MD, PhD, Baylor College of Medicine, 6550 Fannin, Suite 1901, Houston, TX 77030. E-mail gtorre{at}bcm.tmc.edu

Background— The mechanisms that contribute to cardiac allograft hypertrophy are not known; however, the rapid progression and severity of hypertrophy suggest that nonhemodynamic factors may play a contributory role. Tumor necrosis factor-{alpha} (TNF-{alpha}) is a cytokine produced in cardiac allografts and capable of producing hypertrophy and fibrosis; therefore, we suggest that TNF-{alpha} may play a contributory role. Accordingly, the aims of our study were to define the role of systemic hypertension in the development of hypertrophy, characterize the histological determinants of hypertrophy, and characterize the expression of myocardial TNF-{alpha} after heart transplantation.

Methods and Results— To separate the effect of hypertension from immune injury in the development of cardiac allograft hypertrophy, we measured the gain in left ventricular mass by 2D echocardiography in heart transplant recipients and lung transplant recipients who developed similar rates of systemic hypertension. The gain in left ventricular mass was 73% in heart transplant recipients and 7% in lung transplant recipients (P<0.0001). By comparing myocardial samples obtained during the first week after transplant and at 1 year, we found that there was a significant increase in total collagen content (P<0.0001), collagen I (P<0.0001), collagen III (P<0.0001), and myocyte size (P<0.0001). These changes were associated with persistent myocardial TNF-{alpha} expression.

Conclusions— We suggest that the contribution of hypertension to cardiac allograft hypertrophy is minimal and that persistent intracardiac expression of TNF-{alpha} may contribute to the development of cardiac allograft hypertrophy.


Key Words: growth substances • transplantation • hypertrophy




This article has been cited by other articles:


Home page
Eur Heart JHome page
S. S. Kushwaha, E. Raichlin, Y. Sheinin, W. K. Kremers, K. Chandrasekaran, G. J. Brunn, and J. L. Platt
Sirolimus affects cardiomyocytes to reduce left ventricular mass in heart transplant recipients
Eur. Heart J., November 2, 2008; 29(22): 2742 - 2750.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
L. Lin, S. C. Kim, Y. Wang, S. Gupta, B. Davis, S. I. Simon, G. Torre-Amione, and A. A. Knowlton
HSP60 in heart failure: abnormal distribution and role in cardiac myocyte apoptosis
Am J Physiol Heart Circ Physiol, October 1, 2007; 293(4): H2238 - H2247.
[Abstract] [Full Text] [PDF]


Home page
Ann. Thorac. Surg.Home page
M. Wilhelmi, K. Pethig, M. Wilhelmi, H. Nguyen, M. Struber, and A. Haverich
Heart transplantation: echocardiographic assessment of morphology and function after more than 10 years of follow-up
Ann. Thorac. Surg., October 1, 2002; 74(4): 1075 - 1079.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Cell Physiol.Home page
A. Amadou, A. Nawrocki, M. Best-Belpomme, C. Pavoine, and F. Pecker
Arachidonic acid mediates dual effect of TNF-alpha on Ca2+ transients and contraction of adult rat cardiomyocytes
Am J Physiol Cell Physiol, June 1, 2002; 282(6): C1339 - C1347.
[Abstract] [Full Text] [PDF]